VRTX Beginning!
Fundamental & Chart
Not for investment advice, personal notes only
Chart:
identified key area of support, concerning current H&S pattern, potential downside to next support indicate 17% drop. CMF shows weakness, spending a lot of times in the negatives.
So far trend line remains intact, neckline of H&S shows no particular bearish inclination
Fundamentals:
Core product in strong growth, In January 26, 2021, VRTX announced that it received FDA approval for the use of Trikafta with children ages 6-11 with CF and certain mutations.
In January 28, 2021, VRTX announced that it received FDA clearance for its type-1 diabetes investigational medicine and will enter the phase ½ clinical trial.
Powerful toppling and bottom line growth, Net income has grown 229% from 2019 to September 2020.
Currently seeking acquisition opportunities
Let's wait and see
Not for investment advice, personal notes only
Chart:
identified key area of support, concerning current H&S pattern, potential downside to next support indicate 17% drop. CMF shows weakness, spending a lot of times in the negatives.
So far trend line remains intact, neckline of H&S shows no particular bearish inclination
Fundamentals:
Core product in strong growth, In January 26, 2021, VRTX announced that it received FDA approval for the use of Trikafta with children ages 6-11 with CF and certain mutations.
In January 28, 2021, VRTX announced that it received FDA clearance for its type-1 diabetes investigational medicine and will enter the phase ½ clinical trial.
Powerful toppling and bottom line growth, Net income has grown 229% from 2019 to September 2020.
Currently seeking acquisition opportunities
Let's wait and see
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.